HSPG2 and precursor B-cell acute lymphoblastic leukemia: Inhibition of the CXCR4 receptor or the PLC pathway improved survival in Dex-treated NSG mice (NOD SCID gamma mice) and restored sensitivity in Dex-resistant B-ALL cell lines and patient-derived cells [19].